Clinical Trials Logo

Resectable Pancreatic Cancer clinical trials

View clinical trials related to Resectable Pancreatic Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05181488 Active, not recruiting - Clinical trials for Resectable Pancreatic Cancer

Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Start date: April 2, 2020
Phase: N/A
Study type: Interventional

This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.

NCT ID: NCT04472910 Active, not recruiting - Clinical trials for Resectable Pancreatic Cancer

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma

NeoPancOne
Start date: August 21, 2020
Phase: N/A
Study type: Interventional

To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions. The design of this prospective trial will also test our important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in improving outcomes for patients with resectable pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.

NCT ID: NCT03138720 Active, not recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Start date: May 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.